WO1999006045A1 - Controlled release pharmaceutical compositions containing tiagabine - Google Patents
Controlled release pharmaceutical compositions containing tiagabine Download PDFInfo
- Publication number
- WO1999006045A1 WO1999006045A1 PCT/IE1998/000067 IE9800067W WO9906045A1 WO 1999006045 A1 WO1999006045 A1 WO 1999006045A1 IE 9800067 W IE9800067 W IE 9800067W WO 9906045 A1 WO9906045 A1 WO 9906045A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tiagabine
- preparation
- hours
- preparation according
- rate controlling
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Definitions
- This invention relates to controlled release tiagabine formulations and in particular to matrix delivery systems for providing oral controlled release tiagabine formulations, including once or twice daily formulations.
- the anti-epileptic drug tiagabine hydrochloride a nipecotic acid derivative linked to a lipophilic anchor which enables it to cross the blood-brain barrier, potently and specifically inhibits uptake of the inhibitory neurotransmitter ⁇ -aminobutyric acid (GAB A) into astrocytes and neurons.
- GAB A inhibitory neurotransmitter ⁇ -aminobutyric acid
- Tiagabine has shown broad activity against a range of seizure types, including drug-induced, electroshock-induced, light-induced, amygdala-kindled, and audiogenic and has been approved in a number of countries for add-on treatment of adult epileptic patients with complex partial seizures. It is well tolerated and does not cause withdrawal effects or displace other drugs. In humans, tiagabine absorption is rapid and complete. It is metabolized in the liver with a linear process of elimination and a half-life of 5-8 hours. Although tiagabine does not induce or inhibit metabolic processes, it can provide a target for enzyme inducers that can lower its elimination half-life to 2-3 hours. Conventional formulations of tiagabine, such as lOmg formulations, are dosed t.i.d. or q.i.d.
- the mean final dose was 38.4 mg/day (range: 24-54 mg/day) for patients who converted to tiagabine monotherapy.
- median 4-week complex partial seizure rates decreased significantly in patients from both dose groups but significantly more patients in the high-dose group experienced a reduction in seizures of at least 50% compared with the low-dose group.
- US Patent No. 5,010,090 discloses a class of novel compounds, including tiagabine, and their pharmaceutically acceptable salts that exhibit GABA-uptake inhibitory properties useful for the treatment of epilepsy and other CNS related diseases.
- US Patent No. 5,354,760 discloses crystalline tiagabine hydrochloride monohydrate and a process for preparing the same.
- WO 96/34606 discloses tiagabine hydrochloride compositions which include an antioxidant such as ⁇ -tocopherol to stabilize the tiagabine.
- WO 95/29665 discloses a slow-release extended antiepileptic drug dosage form that has an exit in the dosage form for releasing the antiepileptic drug and a lamina between the dosage form wall and the antiepileptic drug formulation to maintain the integrity of the dosage form during the delivery of the antiepileptic drug to the patient.
- this application discloses a diffusion-dosage form that releases a drug by membrane-controlled diffusion, a bioerodible dosage form and a ion-exchange dosage form for administration of antiepileptic drugs selected from the group consisting of hydantoins, barbiturates, deoxybarbiturates, iminostilbenes, succinimides, oxazolidinediones and benzodiazepines.
- antiepileptic drugs selected from the group consisting of hydantoins, barbiturates, deoxybarbiturates, iminostilbenes, succinimides, oxazolidinediones and benzodiazepines.
- antiepileptic drugs phenytoin, carbamazepine, and ethotoin are provided.
- Controlled-release therapeutic dosage forms for tiagabine in which the medicinal substance is incorporated into a matrix would be desirable per se on account of the ease of their manufacture, the low degree of variation between different manufacturing processes and because of the relatively low costs.
- the dosage form control release of the tiagabine in such a manner that an effective concentration in the blood can be maintained over an extended period of time but also the drug release should be such that the drug concentration in the blood remains relatively constant over the extended period of time to improve therapeutic results and/or minimize side effects.
- a controlled-release tiagabine formulation having these properties, especially one having minimal C ax to Cmin peak to trough variations over a period of at least either 12 or 24 hours.
- the present invention provides a controlled release oral pharmaceutical preparation comprising a therapeutically effective amount of tiagabine or a pharmaceutically acceptable salt thereof dispersed in a rate controlling polymeric matrix comprising at least one rate controlling polymer, which preparation provides therapeutically effective plasma levels of tiagabine for a period of at least 12 hours.
- incorporation of tiagabine in the polymeric matrixes according to this invention allows for effective control over the release of tiagabine over time such that administration of the preparation achieves therapeutic levels of tiagabine over extended periods of time in humans, such as for at least 12 hours, and in certain preferred embodiments, for 24 hours or longer.
- therapeutically effective blood levels of tiagabine can be maintained substantially over 24 hours with peak plasma levels occurring between 2 and 18 hours, preferably between 4 and 16 hours, most preferably between 6 and 14 hours.
- tiagabine refers to N-(4,4-di(3-methylthien-2- yl)but-3-enyl) nipecotic acid, including the R and S isomers and racemic mixtures, or a pharmaceutically acceptable salt thereof.
- the preferred pharmaceutically acceptable salt is the hydrochloride salt.
- the R isomer of N-(4,4-di(3-methylthien-2-yl)but-3-enyl) nipecotic acid is preferred and the monohydrate crystalline form of the R isomer of N-(4,4-di(3- methylthien-2-yl)but-3-enyl) nipecotic acid hydrochloride is the most preferred form of tiagabine.
- controlled release it is meant for purposes of the present invention that therapeutically active tiagabine is released from the preparation at a controlled rate such that therapeutically beneficial blood levels (but below toxic levels) of tiagabine are maintained over an extended period of time, e.g., providing a 12 hour or a 24 hour dosage form.
- the preparation releases tiagabine in vivo such that the duration over which the tiagabine plasma concentration is equal to or greater than 50% of the peak plasma concentration (maximum plasma concentration (Cmax)) is 10 hours or greater, more particularly at least 15 hours and especially at least 20 hours.
- Cmax peak plasma concentration
- the in vivo maximum plasma concentration minus the minimum plasma concentration divided by the average plasma concentration [(Cma ⁇ -Cmin)/Cav] taken over the effective period (at least 12 hours, preferably 24 hours) is less than 0.80, more preferably less than 0.60.
- the invention provides controlled release oral dosage forms for tiagabine which provide therapeutic levels of tiagabine for a period of at least 12 hours, preferably 24 hours, having a mean in vitro dissolution profile in aqueous media at 37 °C such that about 5 to 40% of the tiagabine is released after 1 hour; about 25-65% is released after 4 hours; about 55-95% is released after 10 hours and about 80-100% is released after 22 hours when measured according to the USP Apparatus II (paddles) method. More preferably, the in vitro dissolution profile shows release of about 10 to 30% tiagabine after 1 hour; 30 to 60% release after 4 hours; 60 to 90% release after 10 hours and 85 to 100% release after 22 hours.
- the at least one rate controlling polymer is selected from hydroxypropylmethylcellulose, hydroxyalkylcellulose, alkylcellulose, poly(ethylene)oxide, carboxymethylcellulose, hydrophilic cellulose derivatives polyethylene glycols, polyvinylpyrrolidone, or mixtures thereof.
- the rate controlling polymer includes a hydroxypropyl-methylcellulose (HPMC), a hydroxypropylcellulose (HPC), a poly(ethylene oxide), an ethylcellulose or a combination thereof present in an amount of 5 to 75% by weight, more preferably 20 to 50% by weight, most preferably 30 to 45% by weight in the preparation.
- HPMC hydroxypropyl-methylcellulose
- HPC hydroxypropylcellulose
- HPC hydroxypropylcellulose
- HPC hydroxypropylcellulose
- HPC hydroxypropylcellulose
- poly(ethylene oxide) poly(ethylene oxide)
- ethylcellulose or a combination thereof present in an amount of 5 to 75% by weight, more preferably 20 to 50% by weight, most preferably 30 to 45% by weight in the preparation.
- the at least one rate controlling polymer comprises from 19 to 31% by weight of a hydroxypropylmethylcellulose and from 9 to 15% by weight of a hydroxypropylcellulose.
- HPMC HPMC sold under the trademark Methocel (Dow).
- Suitable Methocels include the K grades such as Methocel K15M, Methocel K100M, Methocel K100LV and Methocel K4M. Other suitable Methocels include the E, F and J grades.
- An especially preferred type of HPC for use in accordance with the invention is an HPC sold under the trademark Klucel (Hercules, Inc.) or equivalents. Suitable Klucels include Klucel LF, Klucel JF, Klucel GF, Klucel MF and Klucel HF.
- An especially preferred type of poly(ethylene oxide) for use in accordance with the invention is a poly(ethylene oxide) sold under the trademark Sentry Polyox (Union Carbide Corp.) or equivalents.
- Suitable Polyoxs include the Polyox WSR grades such as Polyox WSR Coagulant, Polyox WSR-301 , Polyox WSR-303, Polyox WSR N-12K, Polyox WSR N-60K, Polyox WSR- 1105, Polyox WSR-205 and Polyox WSR N-3000.
- An especially preferred type of ethylcellulose for use in accordance with the invention is an ethylcellulose sold under the trademark Ethocel (Dow Chemical Co.) or equivalents.
- Figure 1 shows the tiagabine plasma level concentration (ng/ml) over 36 hours following administration of the following 10 mg tiagabine formulations made according to this invention to 12 healthy male volunteers in an open label, randomized, four period cross-over study: Formulation A ( — ⁇ — ) [Batch 8 of Example 4; 20% wt Methocel K15M, 10% wt Klucel LF, Direct Compression]: Formulation B (— ⁇ — ) [Batch 21 of Example 9, 30%wt Methocel K15M, 15%wt Klucel LF, Melt Granulation Type B]; and Formulation C ( — ⁇ — ) [Batch 22 of Example 9, 20% wt Methocel K15M, 10% wt Klucel LF, Melt Granulation Type B].
- the control for this study is the commercially available immediate release tiagabine 10 mg Gabitril (Gabitril is a trade mark) tablets (Novo Nordisk) ( — X — ); and
- Figure 2 illustrates projected steady state plasma tiagabine profiles for Formulation A ( — ⁇ — ) [Batch 8 of Example 4; 20%wt Methocel
- Formulation B ( — ⁇ — ) [Batch 21 of Example 9, 30% wt Methocel K15M, 15%wt Klucel LF, Melt Granulation Type B]; and Formulation C ( — X — ) [Batch 22 of Example 9, 20% wt Methocel K15M, 10% wt Klucel LF, Melt Granulation Type B] at 30mg dosing once daily compared to the conventional Formulation D ( — ⁇ — ) [immediate release tiagabine 10 mg Gabitril (Gabitril is a trade mark) tablets (Novo Nordisk)] dosed lOmg t.i.d.
- rate controlling polymer includes hydrophilic polymers, hydrophobic polymers or mixtures of hydrophilic and/or hydrophobic polymers that are capable of retarding the release of tiagabine in vivo when tiagabine is dispersed in a polymeric matrix formed from the rate controlling polymers.
- rate controlling polymers to be used in this invention include hydroxyalkylcellulose, such as hydroxypropylcellulose and hydroxypropylmethylcellulose; poly(ethylene)oxide; alkylcellulose such as ethycellulose and methylcellulose; carboxymethylcellulose; hydrophilic cellulose derivatives; polyethylene glycol; polyvinylpyrrolidone; cellulose acetate; cellulose acetate butyrate; cellulose acetate phthalate; cellulose acetate trimellitate; polyvinylacetate phthalate; hydroxypropylmethylcellulose phthalate; hydroxypropylmethylcellulose acetate succinate; poly(alkyl methacrylate); and poly (vinyl acetate).
- Other suitable hydrophobic polymers include polymers or copolymers derived from acrylic or methacrylic acid esters, copolymers of acrylic and methacrylic acid esters, zein, waxes, shellac and hydrogenated vegetable oils.
- the hydroxypropylmethylcelluloses used according to the invention preferably have a viscosity (2 wt% solution at 20°C) of about 100 to 100,000 cps, preferably 100 to 30,000 cps. Especially suitable are Methocel K types or their equivalents.
- the hydroxypropylcelluloses used according to the invention preferably have a molecular weight of about 80,000 to 1,150,000, more preferably 80,000 to 600,000. Especially suitable is Klucel LF, which has a molecular weight of 100,000.
- the poly(ethylene oxide) used according to the invention preferably has a molecular weight of about 100,000 to 7,000,000, more preferably 900,000 to 7,000,000.
- Polyox WSR Coagulant which has a molecular weight of 5,000,000.
- the ethylcelluloses used according to the invention preferably have a viscosity of about 3 to 110 cps, more preferably 7 to 100 cps.
- the controlled release preparation of this invention contains about 5 and 75% by weight, preferably about 20 and 50% by weight, more preferably about 30 to 45% by weight rate controlling polymer(s) and about 1 to 40% by weight, preferably about 3 to 25% by weight tiagabine.
- the controlled release preparation according to the invention can preferably include auxiliary agents, such as diluents, lubricants and/or melting binders.
- auxiliary agents such as diluents, lubricants and/or melting binders.
- the excipients are selected to minimize the water content of the preparation.
- the preparation includes an antioxidant.
- Suitable diluents include pharmaceutically acceptable inert fillers such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
- the diluent is suitably a water soluble diluent.
- examples of diluents include microcrystalline cellulose such as Avicel pHl 12, Avicel pHlOl and Avicel pH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose DCL 21; dibasic calcium phosphate such as Emcompress; mannitol; starch; sorbitol; sucrose; and glucose. Diluents are carefully selected to match the specific formulation with attention paid to the compression properties.
- the diluent is preferably used in an amount of 10 to 90% by weight, preferably 25 to 65% by weight, of the controlled release preparation.
- Suitable lubricants including agents that act on the flowability of the powder to be compressed are, for example, colloidal silicon dioxide such as Aerosil 200; talc; stearic acid, magnesium stearate, and calcium stearate.
- Suitable low temperature melting binders include polyethylene glycols such as PEG 6000; cetostearyl alcohol; cetyl alcohol; polyoxyethylene alkyl ethers; polyoxyethylene castor oil derivatives; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene stearates; poloxamers; and waxes.
- polyethylene glycols such as PEG 6000; cetostearyl alcohol; cetyl alcohol; polyoxyethylene alkyl ethers; polyoxyethylene castor oil derivatives; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene stearates; poloxamers; and waxes.
- an antioxidant compound can be included.
- Suitable antioxidants include sodium metabisulfite; tocopherols such as ⁇ , ⁇ , or ⁇ -tocopherol, tocopherol esters and ⁇ -tocopherol acetate; ascorbic acid or a pharmaceutically acceptable salt thereof; ascorbyl palmitate; alkyl gallates such as propyl gallate, Tenox PG, Tenox s- 1 ; sulphites or a pharmaceutically acceptable salt thereof; BHA; BHT; and monothioglycerol.
- the controlled release preparation according to the invention preferably can be manufactured by blending tiagabine with the rate controlling polymer(s) and auxiliary excipients followed by direct compression.
- Other methods for manufacturing the preparation include melt granulation.
- Preferred melt granulation techniques include melt granulation of tiagabine together with the rate controlling polymer(s) and diluent(s) followed by compression of the granules and melt granulation of the tiagabine with subsequent blending of the tiagabine melt granules with the rate controlling polymer(s) and diluents followed by compression of the blend.
- the blend and/or granulate can be screened and/or mixed with auxiliary agents until an easily flowable homogeneous mixture is obtained.
- Oral dosage forms of the controlled release preparation according to the invention can be in the form of tablets or can be multiparticulate, such as in the form of pellets or mini-tablets. If desired, capsules such as hard or soft gelatin capsules, can contain the multiparticulates. If desired, the multiparticulate oral dosage forms can comprise a blend of at least two populations of pellets or mini-tablets having different controlled-release in vitro and/or in vivo tiagabine release profiles. If desired, one of the pellet or mini-tablet populations can comprise immediate release tiagabine multiparticulates, such as multiparticulates formed by conventional means. If desired, the controlled release matrix tablets or multiparticulates of this invention can be coated with a controlled release polymer layer so as to provide additional controlled release properties. Suitable polymers that can be used to form this controlled release layer include the rate controlling polymers listed above.
- the tablets, pellets or mini-tablets according to the invention can be provided with a light-protective and/or cosmetic film coating, for example, film-formers, pigments, anti-adhesive agents and plasticisers.
- a film former may consist of fast-dissolving constituents, such as low- viscosity hydroxypropylmethylcelluose, for example Methocel E5 or D14 or Pharmacoat 606 (Shin-Etsu).
- the film coating may also contain excipients customary in film-coating procedures, such as light-protective pigments, for example iron oxide, or titanium dioxide, anti-adhesive agents, for example talc, and also suitable plasticisers such as PEG 400, PEG 6000, diethyl phthalate or triethyl citrate.
- light-protective pigments for example iron oxide, or titanium dioxide
- anti-adhesive agents for example talc
- suitable plasticisers such as PEG 400, PEG 6000, diethyl phthalate or triethyl citrate.
- oral dosage forms according to the invention are suitable for twice-daily or, more preferably, once-daily administration of tiagabine.
- once-daily oral dosage forms may contain from about 5 to 100 mg tiagabine, preferably 10 to 50 mg tiagabine, and most preferably 20 to 40 mg tiagabine to provide a therapeutic amount of tiagabine throughout the day in a controlled release fashion.
- the rate controlling polymeric matrix of this invention may consist of a hydrogel matrix.
- tiagabine can be compressed into a dosage form containing a rate controlling polymer, such as
- HPMC HPMC, or mixture of polymers which when wet will swell to form a hydrogel.
- the rate of release of tiagabine from this dosage form is controlled both by diffusion from the swollen tablet mass and by erosion of the tablet surface over time.
- the rate of release of the tiagabine may be controlled both by the amount of polymer per tablet and by the inherent viscosities of the polymers used.
- the tiagabine employed in the following examples is the monohydrate crystalline form for the hydrochloride salt of the R isomer.
- the raw material tiagabine hydrochloride monohydrate has high aqueous solubility and consists of fine needle shaped crystals which are relatively cohesive and do not provide good flow properties.
- Powder blends of tiagabine, the rate controlling polymer(s), and, if present, filler(s), diluent(s), lubricant(s) and/or antioxidation agent(s) are blended such as in a V-cone blender and tablet compression is carried out on a single station table press or a rotary tablet press, such as a Fette El rotary tablet press (Wilhelm Fette GMBH) for small scale production or a Horn (Horn of Noack Pharmatechnic GMBH) rotary table press or Fette PI 000 for larger scale production.
- the dissolution rate for the resulting tablets is measured using USP Apparatus II (paddles) at 50 r.p.m. with 900 ml deionized water at 37°C as the dissolution media.
- Controlled release formulations having 30mg tiagabine in 300mg tablets and employing a variety of rate controlling polymers are prepared according to the small scale production procedures given in Example 1.
- Table 1 shows the formulation details and dissolution profiles for these formulations, which all exhibit controlled release over a 12 to 24-hour period.
- the release rates for the formulations containing different Methocel grades show rank order of K100LV (low viscosity) > K15M (intermediate viscosity) > K100M (high viscosity) while the release profile for the formulation containing Polyox, which has a relatively low moisture content compared to the Methocels, is almost equivalent to that of the K15M grade of Methocel.
- Example 3 Direct Compression Formulations
- Controlled release formulations having lOmg tiagabine in 300mg tablets and employing different types of diluents are prepared according to the small scale production procedures given in Example 1.
- Table 2 shows the formulations details and dissolution profiles for these formulations, which all exhibit controlled release over a 12 to 24-hour period.
- Controlled release formulations having lOmg tiagabine in 300mg tablets and employing different rate controlling polymers are prepared according to the larger scale production procedures given in Example 1.
- Table 3 shows the formulation details and dissolution profiles for these controlled release formulations.
- Example 5 Melt Granulation Type A - Diluent(sVmatrix polymer(s) added intragranularly
- the low temperature melting binder(s), the rate controlling polymer(s) and, if desired, filler(s), diluent(s) and/or antioxidation agent(s) are blended such as in a Gral 25L high speed granulator (GEI Collette) prior to the start of the melt process.
- the melt granulation is carried out with a thermal jacket and, if desired, under a nitrogen blanket.
- components such as the antioxidant a tocopherol can be added to the Gral bowl once the melt temperature has been reached.
- lubricant(s) such as talc can be added.
- the resulting blend is tabletted and the dissolution rate for the tablets is measured using USP Apparatus II (paddles) at 50 r.p.m. with 900 ml deionized water at 37°C as the dissolution media.
- Controlled release formulations having lOmg tiagabine in 300mg tablets containing 20% wt and 30% wt Methocel K15M are prepared according to the procedures given in Example 5. Table 4 shows the formulation details and dissolution profiles for these controlled release formulations.
- Example 7 Melt Granulation Type B - Diluents/matrix polvmers(s) added extragranularly
- Tiagabine and other pharmaceutical excipients such as low temperature melting binders and optionally an antioxidant(s) are blended such as in a 24L Gral high speed granulator prior to the start of the melt process.
- the melt granulation is carried out with a thermal jacket and, if desired, under a nitrogen blanket. If desired, components such as the antioxidant a-tocopherol are added to the Gral bowl once the melt temperature has been reached.
- the cooled granulate can optionally be screened such as by passing it through a sieve.
- the granulate is blended with the diluent(s), rate controlling polymers(s) and, optionally other excipients such as silicon dioxide and talc.
- the resulting blend is tabletted and the dissolution rate for the tablets is measured using USP Apparatus II (paddles) at 50 r.p.m. with 900 ml deionized water at 37°C as the dissolution media.
- Controlled release formulations having lOmg tiagabine in 300mg tablets containing Methocel K15M or Polyox WSR are prepared according to the procedures given in Example 7 and tabletted using a
- Controlled release formulations having lOmg tiagabine in 300mg tablets containing Methocel K15M or Polyox WSR are prepared according to the procedures given in Example 7. Batches 21 and 22 were screened through a 600mm sieve and tabletted using a Horn rotary tablet press. Table 6 shows the formulation details and dissolution profiles for these controlled release formulations.
- Figure 1 shows the plasma concentration of tiagabine following administration of formulation A (Batch 8 of Example 4), formulation B (Batch 21 of Example 9), formulation C (Batch 22 of Example 9) and formulation D (Gabitril (Gabitril is a trade mark)).
- Non-compartmental pharmacokinetic analysis of the plasma concentration data resulted in the parameters presented in Table 7.
- the time during which the plasma concentration was greater than 50% of the maximum plasma concentration (mean T50) for formulations A, B and C was calculated to be 22.7 hours, 24.7 hours and 21.1 hours, respectively.
- Formulations A, B and C provide a good extension of plasma drug levels with little loss in relative bioavailability compared to the reference immediate release product. Additionally, these controlled release products effect minimal peak to trough fluctuations in tiagabine blood plasma levels.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69803670T DE69803670T2 (en) | 1997-08-01 | 1998-07-30 | MEDICINE PREPARATIONS WITH TIAGABINE WITH CONTROLLED ACTIVE SUBSTANCE ADMINISTRATION |
CA002299464A CA2299464C (en) | 1997-08-01 | 1998-07-30 | Controlled release pharmaceutical compositions containing tiagabine |
AU86436/98A AU8643698A (en) | 1997-08-01 | 1998-07-30 | Controlled release pharmaceutical compositions containing tiagabine |
EP98937738A EP0991409B1 (en) | 1997-08-01 | 1998-07-30 | Controlled release pharmaceutical compositions containing tiagabine |
JP2000504859A JP2001511450A (en) | 1997-08-01 | 1998-07-30 | Controlled release pharmaceutical composition containing tiagabine |
AT98937738T ATE212550T1 (en) | 1997-08-01 | 1998-07-30 | MEDICINAL PREPARATIONS CONTAINING TIAGABINE WITH CONTROLLED ADMINISTRATION OF ACTIVE INGREDIENTS |
DK98937738T DK0991409T3 (en) | 1997-08-01 | 1998-07-30 | Pharmaceutical controlled release tenagabine-containing preparations |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5443297P | 1997-08-01 | 1997-08-01 | |
US60/054,432 | 1997-08-01 | ||
IE970588 | 1997-08-08 | ||
IE19970588A IE970588A1 (en) | 1997-08-01 | 1997-08-08 | Controlled release pharmaceutical compositions containing tiagabine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999006045A1 true WO1999006045A1 (en) | 1999-02-11 |
Family
ID=26320083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IE1998/000067 WO1999006045A1 (en) | 1997-08-01 | 1998-07-30 | Controlled release pharmaceutical compositions containing tiagabine |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0991409B1 (en) |
JP (1) | JP2001511450A (en) |
AT (1) | ATE212550T1 (en) |
AU (1) | AU8643698A (en) |
CA (1) | CA2299464C (en) |
DE (1) | DE69803670T2 (en) |
DK (1) | DK0991409T3 (en) |
ES (1) | ES2172179T3 (en) |
PT (1) | PT991409E (en) |
WO (1) | WO1999006045A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037302A1 (en) * | 1998-01-22 | 1999-07-29 | Abbott Laboratories | Extended release tiagabine formulations with reduced side-effects |
EP1205190A1 (en) * | 1999-08-04 | 2002-05-15 | Yamanouchi Pharmaceutical Co. Ltd. | Stable medicinal compositions for oral use |
WO2004050064A1 (en) * | 2002-11-29 | 2004-06-17 | Centurion, Inc. | Method of manufacturing controlled release formulation using pelletizer |
US7442387B2 (en) * | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
US9421178B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US10166207B2 (en) | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002325404B2 (en) * | 1998-01-22 | 2006-02-02 | Abbott Laboratories | Extended Release Tiagabine Formulations with Reduced Side-effects |
NZ542303A (en) * | 2003-03-14 | 2008-12-24 | Nirmal Mulye | A process for preparing sustained release tablets |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000171A1 (en) * | 1985-06-26 | 1987-01-15 | Novo Industri A/S | Amino acid derivatives |
WO1995029665A1 (en) * | 1994-04-28 | 1995-11-09 | Alza Corporation | Effective dosage form for antiepileptic drugs |
WO1995031976A1 (en) * | 1994-05-20 | 1995-11-30 | Novo Nordisk A/S | Transdermal delivery of anti-epileptic drugs |
WO1996034606A1 (en) * | 1995-05-05 | 1996-11-07 | Novo Nordisk A/S | Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation |
WO1997002813A1 (en) * | 1995-07-13 | 1997-01-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Non-allosteric gabaa agonists for treating sleep disorders |
WO1997043902A1 (en) * | 1996-05-24 | 1997-11-27 | Smithkline Beecham Corporation | Use of gaba uptake inhibitors as anti-tussive agents |
WO1997047619A1 (en) * | 1996-06-14 | 1997-12-18 | Novo Nordisk A/S | Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
WO1998005330A1 (en) * | 1996-07-31 | 1998-02-12 | Novo Nordisk A/S | Treatment of psychotic disorders |
-
1998
- 1998-07-30 EP EP98937738A patent/EP0991409B1/en not_active Expired - Lifetime
- 1998-07-30 DK DK98937738T patent/DK0991409T3/en active
- 1998-07-30 WO PCT/IE1998/000067 patent/WO1999006045A1/en active IP Right Grant
- 1998-07-30 ES ES98937738T patent/ES2172179T3/en not_active Expired - Lifetime
- 1998-07-30 JP JP2000504859A patent/JP2001511450A/en active Pending
- 1998-07-30 CA CA002299464A patent/CA2299464C/en not_active Expired - Fee Related
- 1998-07-30 DE DE69803670T patent/DE69803670T2/en not_active Expired - Lifetime
- 1998-07-30 PT PT98937738T patent/PT991409E/en unknown
- 1998-07-30 AT AT98937738T patent/ATE212550T1/en active
- 1998-07-30 AU AU86436/98A patent/AU8643698A/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000171A1 (en) * | 1985-06-26 | 1987-01-15 | Novo Industri A/S | Amino acid derivatives |
WO1995029665A1 (en) * | 1994-04-28 | 1995-11-09 | Alza Corporation | Effective dosage form for antiepileptic drugs |
WO1995031976A1 (en) * | 1994-05-20 | 1995-11-30 | Novo Nordisk A/S | Transdermal delivery of anti-epileptic drugs |
WO1996034606A1 (en) * | 1995-05-05 | 1996-11-07 | Novo Nordisk A/S | Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation |
WO1997002813A1 (en) * | 1995-07-13 | 1997-01-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Non-allosteric gabaa agonists for treating sleep disorders |
WO1997043902A1 (en) * | 1996-05-24 | 1997-11-27 | Smithkline Beecham Corporation | Use of gaba uptake inhibitors as anti-tussive agents |
WO1997047619A1 (en) * | 1996-06-14 | 1997-12-18 | Novo Nordisk A/S | Modified form of the r(-)-n-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
WO1998005330A1 (en) * | 1996-07-31 | 1998-02-12 | Novo Nordisk A/S | Treatment of psychotic disorders |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037302A1 (en) * | 1998-01-22 | 1999-07-29 | Abbott Laboratories | Extended release tiagabine formulations with reduced side-effects |
EP1205190A1 (en) * | 1999-08-04 | 2002-05-15 | Yamanouchi Pharmaceutical Co. Ltd. | Stable medicinal compositions for oral use |
EP1205190A4 (en) * | 1999-08-04 | 2004-01-21 | Yamanouchi Pharma Co Ltd | Stable medicinal compositions for oral use |
WO2004050064A1 (en) * | 2002-11-29 | 2004-06-17 | Centurion, Inc. | Method of manufacturing controlled release formulation using pelletizer |
US7442387B2 (en) * | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
US9421178B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9421179B2 (en) | 2011-12-02 | 2016-08-23 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US9427420B2 (en) | 2011-12-02 | 2016-08-30 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US10512621B2 (en) | 2011-12-02 | 2019-12-24 | Synchroneuron, Inc. | Methods of treating posttraumatic stress disorder with acamprosate salts |
US10166207B2 (en) | 2013-06-05 | 2019-01-01 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
Also Published As
Publication number | Publication date |
---|---|
AU8643698A (en) | 1999-02-22 |
EP0991409A1 (en) | 2000-04-12 |
PT991409E (en) | 2002-06-28 |
CA2299464A1 (en) | 1999-02-11 |
DK0991409T3 (en) | 2002-03-25 |
ATE212550T1 (en) | 2002-02-15 |
JP2001511450A (en) | 2001-08-14 |
CA2299464C (en) | 2009-02-17 |
EP0991409B1 (en) | 2002-01-30 |
DE69803670D1 (en) | 2002-03-14 |
DE69803670T2 (en) | 2002-11-21 |
ES2172179T3 (en) | 2002-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6399100B1 (en) | Controlled release pharmaceutical compositions containing tiagabine | |
KR100325494B1 (en) | Sustained-release drug preparations containing tramadol salt | |
EP0440462B1 (en) | Sustained release with high and low viscosity HPMC | |
EP3067043B1 (en) | Pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor | |
EP2066325B1 (en) | Pharmaceutical compositions of aripiprazole | |
US7741374B1 (en) | Methods of use of fenofibric acid | |
KR101774676B1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
JP2009500317A (en) | Release characteristics improved pharmaceutical composition and process for producing the same | |
WO2007054976A2 (en) | Lipid based controlled release pharmaceutical composition | |
IE940953L (en) | Slow release pharmaceutical composition | |
EP2448561B1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
EP2726064B1 (en) | Controlled release oral dosage form comprising oxycodone | |
AU2005263958B2 (en) | Anti-histaminic composition | |
AU2004245029B2 (en) | Controlled release formulations | |
EP0991409B1 (en) | Controlled release pharmaceutical compositions containing tiagabine | |
US20060018962A1 (en) | Sustained release formulation of tramadol | |
KR20080059212A (en) | 3-(2-dimethylaminomethyl cyclohexyl) phenol retard formulation | |
MXPA05001127A (en) | Bicifadine formulation. | |
EP1049470B1 (en) | Extended release tiagabine formulations with reduced side-effects | |
EP1560568B1 (en) | Controlled release pharmaceutical compositions containing sodium alginate and sodium calcium alginate | |
US20030206952A1 (en) | Extended release tiagabine formulations with reduced side-effects | |
AU2002325404B2 (en) | Extended Release Tiagabine Formulations with Reduced Side-effects | |
CZ20002675A3 (en) | Extended release tiagabine formulations with reduced side effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2299464 Country of ref document: CA Ref country code: CA Ref document number: 2299464 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998937738 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998937738 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998937738 Country of ref document: EP |